Zydus Cadila receives final approval from USFDA for Indomethacin Capsules

27 Sep 2017 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Indomethacin Extended-Release Capsules USP, 75 mg. The drug is indicated for use in painful and inflammatory conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute painful shoulder (bursitis and/or tendinitis).

The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 155 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.



Zydus Lifesciences Share Price

922.70 -1.00 (-0.11%)
11-Dec-2025 09:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1781.00
Dr. Reddys Lab 1256.85
Cipla 1496.75
Zydus Lifesciences 922.70
Lupin 2053.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×